Athira Pharma, Inc. (NASDAQ:ATHA) Shares Sold by BML Capital Management LLC

BML Capital Management LLC reduced its stake in Athira Pharma, Inc. (NASDAQ:ATHA) by 14.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,454,362 shares of the company’s stock after selling 250,000 shares during the period. Athira Pharma makes up about 2.7% of BML Capital Management LLC’s investment portfolio, making the stock its 9th biggest holding. BML Capital Management LLC’s holdings in Athira Pharma were worth $3,534,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in ATHA. Clarius Group LLC grew its stake in shares of Athira Pharma by 35.8% during the fourth quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock valued at $130,000 after acquiring an additional 14,124 shares in the last quarter. Laird Norton Trust Company LLC grew its stake in shares of Athira Pharma by 21.3% during the third quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock valued at $361,000 after acquiring an additional 31,400 shares in the last quarter. Nan Fung Group Holdings Ltd grew its stake in shares of Athira Pharma by 1,429.4% during the third quarter. Nan Fung Group Holdings Ltd now owns 180,000 shares of the company’s stock valued at $364,000 after acquiring an additional 168,231 shares in the last quarter. Barclays PLC grew its stake in shares of Athira Pharma by 99.1% during the third quarter. Barclays PLC now owns 435,841 shares of the company’s stock valued at $880,000 after acquiring an additional 216,933 shares in the last quarter. Finally, Marquette Asset Management LLC acquired a new stake in shares of Athira Pharma during the third quarter valued at about $62,000. 57.12% of the stock is currently owned by institutional investors and hedge funds.

Athira Pharma Price Performance

Shares of Athira Pharma stock opened at $2.04 on Wednesday. The business has a 50-day moving average of $2.94 and a 200-day moving average of $2.47. The company has a market capitalization of $78.19 million, a PE ratio of -0.66 and a beta of 2.78. Athira Pharma, Inc. has a 1-year low of $1.33 and a 1-year high of $4.30.

Athira Pharma (NASDAQ:ATHA) last announced its earnings results on Thursday, February 22nd. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.25. On average, equities analysts expect that Athira Pharma, Inc. will post -2.86 earnings per share for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.